Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0346)
| Name |
Hydnocarpin D
|
||||
|---|---|---|---|---|---|
| Synonyms |
Hydnocarpin D; CHEMBL89401
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C25H20O9
|
||||
| IUPAC Name |
5,7-dihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chromen-4-one
|
||||
| Canonical SMILES |
COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4=CC(=O)C5=C(C=C(C=C5O4)O)O)CO)O
|
||||
| InChI |
InChI=1S/C25H20O9/c1-31-20-7-13(2-4-15(20)28)25-23(11-26)32-18-5-3-12(6-21(18)34-25)19-10-17(30)24-16(29)8-14(27)9-22(24)33-19/h2-10,23,25-29H,11H2,1H3/t23-,25-/m1/s1
|
||||
| InChIKey |
ZYWKQKQEAVWKHD-ILBGXUMGSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Mature T-cell lymphoma | ICD-11: 2A90 | ||
| Responsed Regulator | Microtubule-associated proteins 1A/1B light chain 3B {ECO:0000305} (MAP1LC3B) | Driver | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Autophagy | hsa04140 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell autophagy | ||||
| Cell apoptosis | ||||
| In Vitro Model | Jurkat cells | T acute lymphoblastic leukemia | Homo sapiens | CVCL_0065 |
| MOLT4 cells | Adult T acute lymphoblastic leukemia | Homo sapiens | CVCL_0013 | |
| CAM191 cells | Normal | Homo sapiens | CVCL_BS93 | |
| Response regulation | Using T cell acute lymphoblastic leukemia (T-ALL) cell lines Jurkat and Molt-4 as model system, Hydnocarpin D (HD) suppressed T-ALL proliferationin vitro, via induction of cell cycle arrest and subsequent apoptosis. Furthermore, HD increased the MAP1LC3B (LC3-II) levels and the formation of autophagolysosome vacuoles, both of which are markers for autophagy. | |||